How GLP-1 Drugs Are Transforming America’s Taste Buds: Insights from IFF on Changing Food Preferences

Eighty-five percent of people using GLP-1 medications in the U.S. are changing what they eat and drink, according to a report from IFF, a big names in food ingredients. These medications are not just helping with weight loss—they’re altering how users taste food.

GLP-1 drugs can change how sweetness and texture feel, especially at the start. Many users find that foods they used to enjoy, like fatty meals, sweets, and even coffee, suddenly don’t taste good anymore. Instead, they start craving fruits, lean proteins, and plant-based foods. This shift can significantly influence what manufacturers produce, prompting them to create new options that appeal to these consumers.

The medications also come with side effects like dry mouth and digestive issues. This can make even favorite comfort foods unappealing. As a result, IFF suggests that many GLP-1 users end up skipping meals, which can harm their health. They often face problems like fatigue and muscle loss due to missed nutrition.

EFM, an expert in food trends, emphasizes that traditional advice about dieting isn’t resonating with GLP-1 users. Unlike typical weight loss messaging, these consumers need support tailored to their unique journeys. This means shifting the focus from “low-calorie” to “nutrient-rich” options.

Manufacturers are learning to cater to different groups of GLP-1 users. This includes those currently on the medication, those transitioning off it, and those working to maintain their results afterward. Those actively using GLP-1s often need nutrient-dense options that don’t overwhelm their taste buds but still support hydration and digestion.

Recent data shows that households using GLP-1 medications are spending significantly more on meat snacks, yogurt, and nutrition bars, while purchases in categories like chips and soda are declining. A 2024 poll shows that about 12% of U.S. adults have used a GLP-1 drug at some point, with 6% currently using one.

Finance experts suggest that this shift in spending reflects an untapped market. IFF estimates these consumers represent a $56 billion slice of the $939 billion U.S. food and beverage market. As more people adopt GLP-1 drugs, the potential for growth in this sector is huge.

In summary, as GLP-1 medications reshape dietary habits and consumer preferences, the food industry is learning to adapt and innovate. This transformation is not just a new trend but offers long-term opportunities for brands willing to evolve and meet the changing needs of consumers.

For more insights, check out the 2024 KFF Health Tracking Poll, and see how GLP-1 medications are influencing food spending trends.

Source link

GLP-1